ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Impact of comorbidity on survival among men with localized prostate cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 2 syntheses or guidelines pooled it, 310 citations in OpenAlex.
- Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Pooled it
- Early detection of prostate cancer: AUA Guideline.The Journal of urology · 2013Guideline
- Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.JAMA oncology · 2019Trial
- To be screened or not to be screened? Modeling the consequences of PSA screening for the individual.British journal of cancer · 2012Trial
- Predicting disease progression and mortality in prostate cancer using real-world data-driven time-inhomogeneous Markov models.iScience · 2026Article
- [Overtreatment of localized prostate cancer in older men-do we need a new definition of clinical significance?]Urologie (Heidelberg, Germany) · 2026Article
- Demographic, Clinicopathological Characteristics, and Prognosis of 81 Chinese Elderly Patients With Acral Melanoma.Cancer medicine · 2026Article
- Cancer-specific mortality differences between radical prostatectomy and radiotherapy after biochemical recurrence: analysis of a health system-wide cohort.World journal of urology · 2026Article
- Robotic-assisted radical prostatectomy in patients 80+ years: a multi-centre experience.Journal of robotic surgery · 2026Article
- Prostate Cancer: Etiology, Diagnosis, and Treatment.Serican journal of medicine · 2026Article
- Scoring Physician Risk Communication in Prostate Cancer Using Large Language Models.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2026Article
- Commentary: Impact of prognostic nutritional index and geriatric nutritional risk index on prognosis in elderly patients with early-stage prostate cancer.Frontiers in nutrition · 2026Article
- Article
- Scoring Physician Risk Communication in Prostate Cancer Using Large Language Models.medRxiv : the preprint server for health sciences · 2025Article
- [Androgen deprivation therapy of prostate cancer from a geriatric perspective].Zeitschrift fur Gerontologie und Geriatrie · 2025Review
- Additional findings in prostate MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Survival Outcomes for Men over 80 Years Undergoing Transrectal Ultrasound-Guided Prostate Biopsy: A Prospective Analysis.Cancers · 2024Article
- Article
- Reply to: "Preoperative COVID-19 and Postoperative Mortality in Cancer Surgery: Correspondence", by Daungsupawong and Wiwanitkit.Annals of surgical oncology · 2024Article
- Health-related quality of life in ethnically diverse Black prostate cancer survivors: a convergent parallel mixed-methods approach.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo provide patients and clinicians more accurate estimates of comorbidity-specific survival stratified by patient age, tumor stage, and tumor grade. PATIENTS AND
methodsWe conducted a 10-year competing risk analysis of 19,639 men 66 years of age and older identified by the Surveillance, Epidemiology, and End Results (SEER) program linked to Medicare program files. All men were diagnosed with localized prostate cancer and received no surgery or radiation within 180 days of diagnosis. The analysis was stratified by tumor grade and stage and by age and comorbidity at diagnosis classified using the Charlson comorbidity index. Underlying causes of death were obtained from SEER.
resultsDuring the first 10 years after diagnosis, men with moderately and poorly differentiated prostate cancer were more likely to die from causes other than their disease. Depending on patient age, Gleason score, and number of comorbidities present at diagnosis, 5-year overall mortality rates for men with stage T1c disease ranged from 11.7% (95% CI, 10.2% to 13.1%) to 65.7% (95% CI, 55.9% to 70.1%), and prostate cancer-specific mortality rates ranged from 1.1% (95% CI, 0.0% to 2.7%) to 16.3% (95% CI, 13.8% to 19.4%). Ten-year overall mortality rates ranged from 28.8% (95% CI, 25.3% to 32.6%) to 94.3% (95% CI, 87.4% to 100%), and prostate cancer-specific mortality rates ranged from 2.0% (95% CI, 0.0% to 5.3%) to 27.5% (95% CI, 21.5% to 36.5%).
conclusionPatients and clinicians should consider using comorbidity-specific data to estimate the threat posed by newly diagnosed localized prostate cancer and the threat posed by competing medical hazards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.